Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KHK | P50053 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607602 | 0.84 | SLC22A12 (0.49) | SLC22A12HCAR3ALDH1A1HPGD | |
| SCHEMBL3616599 | 0.84 | SLC22A12 (0.49) | SLC22A12ALOX15ALDH1A1HPGD | |
| SCHEMBL25360067 | 0.81 | SLC22A12 (0.39) | SLC22A12ESR1ADORA2AADORA2BHCAR3 | |
| SCHEMBL3602826 | 0.80 | SLC22A12 (0.48) | SLC22A12ALOX15ESR1ADORA2AADORA2B | |
| SCHEMBL3603076 | 0.80 | SLC22A12 (0.46) | SLC22A12ALOX15MAPTKHK | |
| SCHEMBL3604215 | 0.80 | SLC22A12 (0.44) | SLC22A12HCAR3MAPTALDH1A1KHK | |
| SCHEMBL3608064 | 0.79 | SLC22A12 (0.47) | SLC22A12MAPTALDH1A1HPGD | |
| SCHEMBL3608067 | 0.79 | SLC22A12 (0.47) | SLC22A12MAPTALDH1A1HPGD | |
| SCHEMBL3602824 | 0.79 | SLC22A12 (0.47) | SLC22A12MAPTALDH1A1HPGD | |
| SCHEMBL27701244 | 0.76 | SLC22A12 (0.44) | SLC22A12ALOX15ESR1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC22A12 2455/4885ALOX15 2063/4885ESR1 4016/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | SLC22A12 2455/4885ALOX15 2063/4885ESR1 4016/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC22A12 2455/4885ALOX15 2063/4885ESR1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.